Second U.S. jury finds AbbVie misrepresented risks of AndroGel

by reuter.com
http://ift.tt/pnED7n
(Reuters) - A U.S. jury on Thursday ordered AbbVie Inc to pay more than $140 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, the plaintiff's lawyer said in a statement.

Read more

Share on Facebook Share on Twitter Share on Google Plus

About New

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.